Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients

Blood

Volumn 96, Issue 12, 2000, Pages 3712-3718

  Salven, P ^a   Orpana, A ^a   Teerenhovi, L ^a   Joensuu, H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ARTICLE; BLOOD SAMPLING; CANCER GRADING; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE COUNT;

EID: 0034548821     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.3712     Document Type: Article

References (58)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. Angiogenesis: A dynamic balance of stimulators and inhibitors
4. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
5. The biology of vascular endothelial growth factor
6. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction
7. Biological roles of fibroblast growth factor-2
8. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells
9. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells
10. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
11. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
12. Inhibition of tumor growth and metastasis by an immuno-neutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121
13. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
14. Suppression of solid tumor growth by immuno-neutralizing monoclonal antibody against human basic fibroblast growth factor
15. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer
16. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
17. Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients
18. Serum vascular endothelial growth factor is often elevated in disseminated cancer
19. Circulating vascular endothelial growth factor in patients with colorectal cancer
20. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer
21. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer
22. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
23. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
24. Vascular endothelial growth factor serum concentrations in ovarian cancer
25. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate
26. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer
27. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
28. Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy
29. Basic fibroblast growth factor in serum and urine of patients with head and neck cancer
30. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine
31. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
32. National Cancer Institute-sponsored study on classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
33. International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma
34. Distribution of intravenously administered acidic and basic fibroblast growth factors in the mouse
35. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
36. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
37. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
38. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
39. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas: An immunohistochemical and ultrastructural study
40. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas
41. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels
42. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
43. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
44. Placenta growth factor (PIGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid
45. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
46. Constitutive and selective expression of basic fibroblast growth factor in human leukaemia cell lines
47. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role
48. + T cells
49. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells
50. TGF-beta regulates production of growth factors and TGF-beta by human peripheral blood monocytes
51. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis
52. Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells
53. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia
54. Basic fibroblast growth factor secreted by an animal tumor is detectable in urine
55. Treatment of non-Hodgkin's lymphoma
56. Isolation and characterization of the circulating form of human endostatin
57. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin
58. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth